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Background: Septic shock is the most severe phase of sepsis and is associated with high rates of mortality.
However, early stage prediction of septic shock outcomes remains difficult. Metabolomic techniques have emerged
as a promising tool for improving prognosis.
Methods: Orthogonal projections to latent structures-discriminant analysis (OPLS-DA) models separating the serum
metabolomes of survivors from those of non-survivors were established with samples obtained at the intensive care
unit (ICU) admission (H0) and 24 h later (H24). For 51 patients with available H0 and H24 samples, multi-level
modeling was performed to provide insight into different metabolic evolutions that occurred between H0 and H24
in the surviving and non-surviving patients. Relative quantification and receiver operational characteristic curves
(ROC) were applied to estimate the predictability of key discriminatory metabolites for septic shock mortality.
Results: Metabolites that were involved in energy supply and protein breakdown were primarily responsible for
differentiating survivors from non-survivors. This was not only seen in the H0 and H24 discriminatory models, but
also in the H0-H24 paired models. Reanalysis of extra H0-H24 paired samples in the established multi-level model
demonstrated good performance of the model for the classification of samplings. According to the ROC results,
nine discriminatory metabolites defined consistently from the unpaired model and the H0-H24 time-trend change
(ΔH24-H0) show good prediction of mortality. These results suggest that NMR-based metabolomic analysis is useful
for a better overall assessment of septic shock patients.
Conclusions: Dysregulation of the metabolites identified by this study is associated with poor outcomes for septic
shock. Evaluation of these compounds during the first 24 h after ICU admission in the septic shock patient may be
helpful for estimating the severity of cases and for predicting outcomes.
Trial registration: All human serum samples were collected and stored, provided by the “center of biologic
resources for liver disease”, in Jean Verdier Hospital, Bondy, France (BB-0033-00027).
Keywords: 1H nuclear magnetic resonance spectroscopy, Metabolomics, Septic shock, Outcome prediction© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: philippe.savarin@univ-paris13.fr
2Sorbonne Paris Cité, Laboratoire de Chimie, Structures et Propriétés de
Biomateriaux et d’Agents Therapeutiques, UMR 7244, University Paris 13,
F-93017 Bobigny, France
Full list of author information is available at the end of the article
Liu et al. Critical Care          (2019) 23:169 Page 2 of 12Background
Septic shock is the most severe phase of sepsis [1, 2]. It
is defined as sepsis complicated either by hypotension
that is refractory to fluid resuscitation or by hyperlacta-
cidemia and is often accompanied by acute organ failure.
Mortality rates associated with septic shock are 20 to
30% in many series, principally due to multiple organ
dysfunction syndrome (MODS) [3]. Common strategies
for the treatment of septic shock include prompt initi-
ation of therapy to treat the underlying infection with
antibiotics, vasopressor therapy, and support for failing
organs. In recent years, early goal-directed therapy
(EGDT), which improves curative effect, has been exten-
sively applied to improve rescue outcomes [4, 5]. How-
ever, early personalized prognosis and diagnosis remain
challenging due to the complicated etiology and patho-
genesis of septic shock. Determination of an acute prog-
nosis in the early stage of sepsis is of great importance
to improve therapeutic efficacy and will aid in the devel-
opment of adapted strategies for different cases. In fact,
evaluation of existing biomarkers (e.g., TNF-α, IL-6, and
PCT) and clinical scores such as the sequential organ
failure assessment (SOFA) [6] have been applied prog-
nostically but their performance (sensitivity, specificity)
has not proven adequate for all cases [7]. Thus, new
methods for reliable early prognosis are still urgently
needed.
Metabolomics has been proven to be a promising tool
that aid in the prognosis of sepsis. This is because meta-
bolomics allows to provide comprehensive information
of personalized metabolome and therefore to enable the
prediction of personalized outcome for septic patients.
Previous studies have shown that there are considerable
differences in the metabolome fingerprints between sep-
tic shock survivors and non-survivors. However, notably,
most of the previous studies in human septic patients
were designed to be performed by analysis of one unique
sampling, and no studies have derived dynamic alter-
ations of patient metabolomes during clinical therapy.
However, good outcomes for septic shock are associated
with a less severe disease course and a positive thera-
peutic response to treatment. In a previous study, we re-
ported comprehensive differences in the metabolic
profiles between septic shock survivors and
non-survivors at the admission to the intensive care unit
(ICU), based on a liquid chromatography-mass spec-
trometry (LC-MS) approach [8]. In this current study,
samples from the septic shock patients which were ob-
tained 24 h after ICU admission were also included. The
aim of the present study was to analyze the discrimin-
atory ability of metabolic profiles between septic shock
survivors and non-survivors at the beginning and 24 h
after ICU admission and also to describe the evolution
of metabolic profiles for septic shock patients during thisperiod by using 1H NMR spectroscopy-based
metabolomics.
Materials and methods
Patient inclusion
Between January 2009 and December 2011, all consecu-
tive adults admitted to our intensive care unit were en-
rolled in this study if they had an indisputable or
probable septic shock in the first 24 h after ICU admis-
sion [9]. Septic shock was defined as the presence of a
clinically or microbiologically documented infection and
on-going treatment with vasopressor therapy (norepin-
ephrine or epinephrine at a dose ≥ 0.25 μg per kilogram
of body weight per minute or at least equal to 1 mg per
hour) for at least 6 h to maintain a systolic blood pres-
sure of at least 90 mmHg or a mean blood pressure of at
least 65 mmHg. Non-inclusion criteria were (i) patient
younger than 18 years, (ii) patient with solid cancer or
blood cancer, and (iii) patient with liver cirrhosis or
chronic kidney disease. Patients were treated according
to the international guidelines for the management of
sepsis and shock septic [5].
Biological parameters, hemodynamic parameters, and
the use of catecholamine and mechanical ventilation
were recorded at inclusion. Cause of septic shock was
recorded. To evaluate the severity of the disease, the Se-
quential Organ Failure Assessment (SOFA) score was
calculated during the first day of admission [10]. ICU
and hospital length of stay and mortality were recorded.
The survival status of each patient was noted 7 days after
the first sample.
Sample collection
All the first samplings (H0) were obtained withdrawn
just before or immediately after clinical vasopressor ther-
apy initiation on the patients. The second samples were
withdrawn 24 h after the beginning of the vasopressor
introduction. Blood samples were collected in serum
separator tubes (SST). SST were stored for at least 30
min and not more than 1 h and 30min. After centrifuga-
tion (1000×g, 25 °C, 10 min), the serum was stored at
−80 °C. All human serum samples were collected and
stored, provided by the “center of biologic resources for
liver disease”, in Jean Verdier Hospital, Bondy, France
(BB-0033-00027). Written informed consent was ob-
tained from all subjects or their surrogate
decision-maker. The local ethics committee approved
the protocol.
Regrouping and matching of samples
As shown in Fig. 1, 122 samples from 70 patients were
obtained. Seventy samples were drawn at ICU admission
and are noted as H0 samples. 52 samples were obtained
24 h after the first sampling and are noted as H24
Fig. 1 Regrouping and matching of samples. One H24 sample from a survivor was excluded due to the problem of NMR gain parameter; one H0
sample from a non-survivor was excluded as it was found to be an outlier in PCA. For the paired H0-H24 samples obtained from the same
patients, the pairs have been divided into training set and test set. The pairs of survivors and non-survivors were analyzed separately. Samples in
the training set were analyzed for establishing discriminatory models between H0 and H24 samples. The pairs in the test set were reanalyzed in
the established models
Liu et al. Critical Care          (2019) 23:169 Page 3 of 12samples. During analysis, one H0 sample from a
non-survivor who did not have a matching H24 sample
was excluded as a spectral outlier. One H24 sample from
a survivor was excluded while the H0 sample that
belonged to the same patient was retained. The exclu-
sion of the sample was due to the drastically affected
NMR gain parameter. The spectrum of this sample was
therefore found to be clearly different from the others.
Among the non-survivors, 11 patients died prior to the
H24 sampling and their H24 samples were therefore not
available. For the other samples, each H24 sample was
matched with the H0 sample which was collected from
the same patient. In this case, 32 pairs for survivors and
19 pairs for non-survivors were obtained. For both septic
shock survivor (SSS) and non-survivor (SSN) H0-H24
pairs, two thirds were randomly taken into the training
set while the remaining were put into the test set.
Sample preparation and NMR data acquisition
Samples were defrosted at room temperature. A volume
of 450 μL of each sample was diluted with 50 μL of D2O
in an NMR tube of 5 mm diameter. All the samples were
then analyzed with a 500-MHz NMR spectrometer (Ad-
vance III, Bruker, Germany) at 297 K. The free induction
decay (FID) signals were collected onto 64k data points,
with a spectral width of 6000 Hz. The 1D 1H NMRspectra were recorded by the Carr-Purcell-Meiboom-Gill
(CPMG) sequence [11] with 128 transients for each
spectrum. For several samples, 2D NMR experiments
(TOCSY and JRES sequences) were achieved to confirm
spectral assignments. The mixing time of the TOCSY
spectra was 80ms with 32 transients.
Data processing
After the FIDS were acquired for all the samples, they
were processed using the NMRPipe software [12]. All
FIDs were multiplied by a 0.3-Hz exponential line
broadening factor prior to Fourier transformation. Phas-
ing of each spectrum was manually adjusted, and base-
lines were corrected using a linear method. All the
spectra were divided into 0.001 ppm buckets between −
1 and 10 ppm. The residual water signal (4.6 to 5.5 ppm)
was excluded, and the spectral region from 3.16 to 4
ppm was also removed since signals observed in this
section represented the infusion of hydroxyethyl starch
(HES), which was applied in the ICU to heighten blood
tension for the patients who suffered from hypotension.
The spectra were then normalized using the probabilistic
quotient method [13]. All the buckets were centered by
the method of auto-scaling. The peaks were adequately
assigned using the Human Metabolome Database
(HMDB, www.hmdb.ca) NMR library, the Chenomx
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ments. As to the annotation of NMR peaks, an exemplar
NMR spectrum has been shown in Additional file 1: Fig-
ure S1 with some of the assignments.
Statistical analyses
All the multivariate analyses were achieved using an
in-house code which is based on the code of Trygg and
Wold [14], developed using Matlab software (version
2012b, MA, USA). Prior to the establishment of discrim-
inatory analyses, a principal component analysis (PCA)
with H0 samples from all the included non-survivors
shows that the main variability among these samples does
not correspond to the time of the death, as shown in Add-
itional file 1: Figure S2. Another PCA for all the acquired
spectra was performed to ensure that there were no out-
liers (Additional file 1: Figure S3). Orthogonal projections
to latent structures-discriminant analyses (OPLS-DA)
were performed for differentiating survivors from
non-survivors with H0 and H24 samples, respectively.
Samples obtained at H0 and H24 from the same patients
were paired and analyzed in multilevel models to study
the interindividual variability [15]. The paired samples
were divided into survivor and non-survivor groups. Two
OPLS-DA multilevel models were applied with the survi-
vors and non-survivors, respectively, separating H0 from
H24 samples. The models were all validated by
cross-validation with 500 permutations of variable X and
Y, where X represents the data matrix and Y represents
the discriminatory variable for each model [15, 16]. For
the univariate analyses analyzing the significant differences
between two groups, the P values were calculated with
Student’s T test. The false discovery rate (FDR) was calcu-
lated by the Multiple Experiment Viewer Toll (version
4.9.0, OriginLab, Northampton, USA); the correction of P
value is performed with “adjusted Bonferroni correction”
[17]. The threshold of FDR was set at 0.1 for the screening
of the discriminatory metabolites, that is, the variables
with FDRs superior to 0.1 were not considered as import-
ant discriminants. A significant difference between com-
pared groups was defined with an adjusted P value
inferior to 0.05.
Results
Baseline characteristics of patients
The baseline biological characteristics of all the included
patients are shown in Table 1. Partial pressure of arterial
oxygen (PaO2) and the ratio of PaO2 to the percentage
of inspired oxygen (FiO2) were significantly different be-
tween the survivors and non-survivors at H0. Lactate
level in non-survivors was also found to be significantly
increased than those in survivors. For the clinical scores,
SAPSII and SOFA, SAPSII was able to discriminate be-
tween survivors and non-survivors. However, due to thesample size, it was not satisfying to predict mortality
with SOFA in this study, according to the results both at
H0 and H24.
Discriminatory analyses separating septic survivors from
non-survivors with samples drawn before treatment (H0)
For the H0 samples, a total of 69 samples were analyzed
using an OPLS-DA model (PCA models separating the
survivors from the non-survivors prior to the exclusion
of the outlier have been illustrated in Additional file 1:
Figure S3). Among these, 40 samples were obtained
from survivors and 29 were from non-survivors. As is
shown in Fig. 2a for H0, a clear separation between the
two groups of patients is demonstrated by the score plot.
The Q2Y, which indicates the predictability of the model,
was equal to 0.60 with three components, and the R2Y,
which indicates the fraction of explained variance of the
Y variable, was 0.75, where Y corresponded to the sur-
vival condition in the model for the SSS vs. SSN com-
parison. Cross-validation showed that the model was not
over-fitted (Additional file 1: Figure S4). In the loading
plot (Fig. 2c), the peaks are colored according to the cor-
relation coefficients, which relate to their contribution
to the discriminatory model. Corresponding discrimin-
atory metabolites have been listed in Table 2 with their
chemical shifts, multiplicity, correlations, variance im-
portance projections (VIPs), and P values. The concen-
trations of various amino acids such as alanine,
glutamate, glutamine, methionine, and aromatic amino
acids were increased in the non-survivors as compared
to the survivors. Significant variations between the two
groups were also found in energy-associated metabolites
including two tricarboxylic acid (TCA) cycle intermedi-
ates, citrate and fumarate, and lactate and pyruvate. Ke-
tone bodies, 3-hydroxybutyrate, and acetate were also
elevated in the non-surviving patients. The only de-
creased signal was observed for the N-acetyl moieties of
glycoproteins. Together, the results showed considerable
differences in the metabolic profiles between the survi-
vors and the non-survivors at H0.
Discriminatory analyses separating septic survivors from
non-survivors with samples drawn 24 h after ICU
admission (H24)
A second OPLS-DA model differentiating metabolic
profiles of SSS from those of SSN were performed with
51 H24 samples. Of these samples, 19 non-survivors
were compared with 32 survivors. As shown in Fig. 2b, a
separation between SSS and SSN was observed. The R2Y
and Q2Y values in the model were equal to 0.86 and
0.46, respectively, and were calculated with three com-
ponents. The validation by permutations is shown in
Additional file 1: Figure S5. Significant discriminant me-
tabolites were identified referring to the loading plot
Table 1 Baseline characteristics of the patients recorded at admission to the ICU
Total/average Survivors Non-survivors Adj P FDR
Number of patients 70 40 30
Male (%) 40 (57%) 27 (67%) 13 (32%) 0.07 0.09
Age 70.1 ± 0.16 68.5 ± 0.29 72.1 ± 0.36 0.12 0.23
Temperature (°C) 37.3 ± 0.02 37.1 ± 0.03 36.9 ± 0.05 0.32 0.35
Mean arterial pressure (mmHg) at admission 72.8 ± 2,44 71,0 ± 3,25 75.2 ± 3.72 0.41 0.35
pH at admission 7.3 ± 0.00 7.31 ± 0.00 7.29 ± 0.00 0.43 0.53
PaO2 (mmHg)H0 144.7 ± 1.54 167.5 ± 2.83 113.6 ± 3.12 0.05 0.13
PaCO2 (mmHg) 37.6 ± 0.18 37.6 ± 0.31 37.5 ± 0.45 0.66 0.63
PaO2/FiO2 ratioH0 212.5 ± 4.10 168.6 ± 3.19 242.2 ± 5.59 0.04 0.07
Lactate (mmol/L)H0 5.0 ± 0.07 3.7 ± 0.11 6.6 ± 0.17 0.01 0.03
Creatininemia (μmol/L)H0 212.2 ± 3.88 200.1 ± 4.34 241.9 ± 3.55 0.07 0.15
Glycemia (mmol/L) 9.8 ± 0.09 9.9 ± 0.20 9.6 ± 0.23 0.91 0.95
Hemoglobin (mmol/L) 10.5 ± 0.03 10.1 ± 0.06 10.9 ± 0.07 0.09 0.06
Albumin (g/L) 24.6 ± 0.13 22.2 ± 0.15 26.8 ± 0.38 0.11 0.21
Platelet (g/L) 156.7 ± 1.53 151.8 ± 2.61 162.2 ± 3.70 0.33 0.13
Total bilirubin (μmol/L) 38.4 ± 0.90 37.8 ± 1.90 39.1 ± 1.53 0.54 0.77
CRP (mg/dL) 162.3 ± 2.15 174.0 ± 3.98 147.4 ± 4.71 0.49 0.67
PCT (mg/dL) 25.2 ± 0.52 28.0 ± 1.15 21.6 ± 1.39 0.74 0.88
SAPSII 59.0 ± 0.24 55.2 ± 0.39 64.3 ± 0.58 0.02 0.07
SOFAH0 11.7 ± 0.06 10.9 ± 0.11 12.4 ± 0.12 0.10 0.15
SOFAH24 9.4 ± 0.06 8.7 ± 0.11 10.3 ± 0.10 0.07 0.11
ICU LOS (day) 9.16 ± 1.21 15.1 ± 1.36 3.62 ± 0.09 0.05 0.09
Mechanical ventilation (%) 84% 75% 93%
Hospital-acquired infection (%) 45% 35% 60%
Sepsis causes (%)
Pulmonary 54% 55% 53%
Abdominal 30% 22% 40%
Urinary tract 7% 7% 6%
Others 8% 15% 0%
All the data is represented as mean ± standard error of mean (SEM)
PaO2 partial pressure of arterial oxygen, FiO2 percentage of inspired oxygen, SOFA Sepsis-related Organ Failure Assessment, SOFAH0 SOFA measured at H0,
SOFAH24 SOFA measured at H24, SAPSII new simplified acute physiology score, LOS length of stay, FDR false discovery rate, Adj P P value adjusted with
Bonferroni correction
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ing levels of most amino acids and energy-related me-
tabolites, as well as the decreases of N-acetyl moieties of
glycoproteins, were still detected in SSN, compared with
SSS, in line with the findings of the H0 model. Besides,
an increase in ketone bodies and diminishing
lipid-related signals were only present at H24, but not at
H0, in the non-survivors when compared to survivors.
Both H0 and H24 unpaired models revealed extensive
variations in the metabolic profiles between SSS and
SSN at the admission and 24 h after ICU admission.
Discriminatory analysis of the evolution of septic shock
from H0 to H24 for septic shock survivors and non-
survivors
On the basis of the separation found between SSS and
SSN within the above two discriminant models, wehypothesized that the therapeutic response between SSS
and SSN could be different. To verify this hypothesis,
SSS and SSN groups were compartmentalized and stud-
ied by two multi-level OPLS-DA models which focused
on the intraindividual variability of the metabolome be-
tween H0 and H24. The pairwise distance of metabo-
lome variations between H0 and H24 samples were
analyzed for the patients for whom both H0 and H24
samples were collected.
For the SSS group, 21 pairs were randomly included to
establish a model separating the H0 sample from the
H24 sample, as shown in Fig. 3a. The Q2Y was 0.78 with
2 components, and R2Y was 0.94. This model was subse-
quently applied to 11 other pairs. The predictions for
these pairs are shown in Fig. 3b. R2Y for the prediction
was 0.76, showing a prominent prediction of the classifi-
cation among H0 and H24 samples. For the SSN model,
Fig. 2 OPLS-DA between septic shock survivors and non-survivors at H0 and H24. a, b Score plots for the H0 and H24 models, respectively. Blue
dots represent the survivors and yellow dots represent the non-survivors. Tpred: The components that predict the differences between the groups;
Torth: components that do not predict the differences between the groups; c, d Loading plot for the H0 and H24 models, respectively. The color
of the peaks indicates the correlation between the marked peak and the classification of the sample. Colors that are close to red correspond to a
higher correlation. Positive peaks in the loading plot correspond to metabolites which increased in non-survivors; negative peaks correspond to
metabolites that decreased in non-survivors
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served, as shown in Fig. 3c. Thirteen pairs were used to
set up a training model, and 6 pairs were included in the
test set. Consequently, R2Y and Q2Y were 0.57 and 0.91,
respectively, and R2Y for the reanalysis was 0.33 (as
shown Fig. 3d). The loading plots for the two paired
models are shown in Additional file 1: Figure S6. Metab-
olites which are listed in Table 4 exhibited opposite
H0-H24 metabolome evolutions between SSN and SSS.
Accordingly, increases of amino acids, energy-related
metabolites, and creatinine and a decline of glycoprotein
could be observed during the evolution from H0 to H24
for the non-survivors. However, this was not the case for
survivors.
Discrimination between SSS and SSN based on the
relative quantification of key discriminators
Spectral signals corresponding to the metabolites in
Table 4 were integrated for the spectra of paired sam-
ples. As shown in Table 4, the molecules variedoppositely during the H0-H24 evolution between the
survivors and non-survivors. The time-trend change
of area, ΔSignal areaH24-H0, was calculated for each
metabolite. Average values for ΔSignal areaH24-H0 of
involved metabolites resulting from the SSN model
were compared to those from the SSS model, as
shown in Fig. 4a. Interestingly, the metabolites were
also shown to be discriminant variables in the com-
parison between SSS and SSN in previously men-
tioned H0 and H24 unpaired models. We further
calculated the area under the ROC curve for the me-
tabolites in order to test their performance in the
classification of surviving patients. ROCs for the dis-
criminant metabolites in the H0 and H24 models, as
well as for ΔH24-H0, were performed and are shown in
Table 5. Accordingly, based on our data, most ROCs
for the metabolites showed slightly better perform-
ance in the classification of survival than SAPSII and
SOFA, not only within the H0 and H24 models, but
also with the value of ΔH24-H0.
Table 2 Metabolites found to discriminate between SSS and
SSN at H0
Peaks Assignment VIP Correlation Adj P FDR
1.06d 3-Hydroxyisobutyrate 3.06 0.52 0.0001 0.0001
5.79s Urea 2.64 0.45 0.002 0.003
7.31m 7.36m Phenylalanine 2.64 0.44 0.01 0.01
2.12m, 2.32m Glutamate 2.6 0.44 0.02 0.02
2.43m Glutamine 2.55 0.43 0.03 0.01
3.03s Creatinine 2.43 0.41 0.03 0.04
1.32d 4.11q Lactate 2.38 0.4 0.02 0.04
2.14s Methionine 2.17 0.37 0.06 0.05
1.46d Alanine 2.12 0.26 0.07 0.08
6.88d 7.18d Tyrosine 2.02 0.34 0.03 0.04
2.36s Pyruvate 2.01 0.34 0.03 0.01
2.52d 2.62d Citrate 1.94 0.33 0.03 0.04
1.7m Lysine 1.91 0.27 0.09 0.08
6.52s Fumarate 1.9 0.32 0.04 0.05
7.67s 1-Methylhistidine 1.66 0.28 0.07 0.06
2.03s Glycoprotein (N-acetyl) 1.64 − 0.28 0.08 0.03
1.91s Acetate 1.56 0.25 0.09 0.10
1.16d Isopropanol 1.53 0.26 0.09 0.03
Chemical shifts for the assigned metabolites are shown in the peak column.
The superscripts for the peaks represent the multiplicity of the peaks. s,
singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet. A positive correlation
indicates an increased level of the metabolite in the non-survivor while
negative correlation indicates a decreased level of the metabolite. The
threshold of FDR was set at 0.1. Similar expressions are also applied for
Tables 3 and 4
Adj P P values that are calculated by Student’s T test are adjusted with
Bonferroni correction, FDR false discovery rate
Table 3 Metabolites found to discriminate between SSS and SSN at
Peaks Assignment Corre
2.37s Pyruvate 0.52
2.52d 2.62d Citrate 0.52
7.31m 7.36m Phenylalanine 0.48
6.88d, 7.18d Tyrosine 0.45
2.72m Lipids (fatty acid residues) − 0.44
2.43m Glutamine 0.44
1.32d, 4.41q Lactate 0.44
1.06d 2-Hydroxyisovalerate 0.41
3.03s Creatinine 0.37
2.03s Glycoprotein (N-acetyl) − 0.37
7.03s 7.67s 1-Methylhistidine 0.35
2.12m,2.33m Glutamate 0.33
1.7m Lysine − 0.29
1.46d Alanine 0.28
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Effective prognosis can help to improve outcomes for
septic shock patients. However, septic shock prognosis
can be complicated by patient-specific factors that affect
responsiveness to therapy. With the use of metabolomic
techniques, we have determined the serum metabolome
fingerprint of septic shock patients with both H0 and
H24 samples. We also investigate the metabolic foot-
print along with the evolution from H0 to H24. To our
knowledge, our study is the first to reveal time-trend
metabolic differences using NMR-based metabolomics
between septic shock survivors and non-survivors within
24 h after ICU admission.
Metabolic variations for H0 and H24 unpaired models
separating SSS from SSN
The H0 and H24 unpaired models reveal the differences
of metabolome fingerprint between SSS and SSN at the
admission to ICU and at 24 h after the admission. Re-
garding the common discriminatory metabolites found
in both models, consistent increases in energy-related
metabolites, creatinine, 1-MH, and several amino acids,
as well as decreases in glycoproteins are observed as im-
portant signals in the non-survivors. Such variations
found in SSN at both H0 and H24 are likely to reflect
more severe sepsis-induced inflammatory responses and
organ dysfunctions that contribute to poor outcomes.
The deregulation of TCA cycle intermediates, such as
more concentrated citrate found in the SSN, is one of
the consequences of severe stress induced by sepsis [18].
Stress also results in an unregulated catabolism [19]. En-
hanced degradation of glycoproteins indicates an aggra-
vated stress in the non-survivors. Also, increases in
various amino acids and ketone bodies at H24 in the24 h after admission to ICU
lation VIP Adj P FDR
3.55 0.0001 0.0001
3.5 0.0002 0.0003
3.25 0.001 0.001
3.03 0.004 0.004
2.99 0.01 0.01
2.96 0.01 0.01
2.9 0.01 0.02
2.77 0.02 0.03
2.51 0.03 0.05
2.48 0.05 0.05
2.37 0.06 0.07
2.22 0.07 0.09
1.95 0.09 0.07
1.9 0.13 0.10
Fig. 3 Score plots of OPLS-DA separating H0 from H24. For the patients whose H0 and H24 are both available, their H0 and H24 samples are
matched in the discriminatory models. The pairs from the survivors and non-survivors are analyzed in two separated paired models. Blue dots
represent the H24 samples and yellow dots represent the H0 samples. a Score plot for the training set separating H0 from H24 for the survivors.
b Reanalysis of test set samples of survivors in the established H0-H24 multi-level model. c Score plot for the training set separating H0 from H24
for the non-survivors. d Reanalysis of test set samples of non-survivors in the established H0-H24 multi-level model
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and enhanced lipid oxidation [20]. Notably, ketone bod-
ies have recently been reported to be immune suppres-
sors [21], and elevations in these metabolites may
contribute to a negative response in critical illness [22].
Our results also provide evidence for the metabolic vari-
ations that are associated with severe organ dysfunction in
non-survivors. As shown in Table 1, significantly lower
oxygen pressures with higher blood lactate levels indicateTable 4 Discriminatory metabolites with different variations along th
survivor group
Peaks Assignment C1 Adj P1
2.12m 2.32m Glutamate − 0.62 0.0001
2.52d 2.66d Citrate − 0.59 0.0001
7.32d 7.36d Phenylalanine − 0.53 0.0004
2.07m 2.43m Glutamine − 0.49 0.001
1.47d Alanine − 0.42 0.004
1.32d 4.11q Lactate − 0.62 0.0001
2.37s Pyruvate − 0.38 0.04
2.03s Glycoprotein (N-acetyl) 0.26 0.08
3.02s Creatinine − 0.21 0.15
C1, correlation of the metabolite to the discriminatory model for the survivors; C2, c
For each listed metabolite, the sign of C1 is opposite to that of C2; Adj P1, adjusted
between H0 and H24 samples for the survivors; Adj P2, adjusted P value of the met
FDR1, false discovery rate for the P value calculated with the survivors; FDR2, false d
concentration for the metabolites from H0 to H24 for the survivors; V2, variation in
increased concentration of the metabolite at H24 compared with H0; ↓, decreased
(Adj P > 0.05) variationthe presence of more severe hypoxia in the non-survivors
than in survivors. This may be due to mitochondrial dis-
order, defective TCA cycle [23], which results in damp-
ened aerobic respiration and abnormal energy supply.
Severe disorders in energy supply should be an import fac-
tor inducing organ failure [24–26]. Other variations in-
volving organ dysfunction are found in creatinine and
1-MH. Their elevations in the comparison in SSN are also
supported by some other previous studies [27, 28].e H0-H24 evolution between the non-survivor group and the
FDR1 V1 C2 Adj P2 FDR2 V2
0.001 ↓ 0.49 0.03 0.02 ↑
0.001 ↓ 0.59 0.002 0.004 ↑
0.003 ↓ 0.4 0.08 0.07 ↑
0.01 ↓ 0.44 0.03 0.03 ↑
0.03 ↓ 0.42 0.05 0.06 ↑
0.002 ↓ 0.2 0.26 0.21 NS
0.05 ↓ 0.06 0.42 0.33 NS
0.09 NS − 0.48 0.01 0.01 ↓
0.13 NS 0.47 0.02 0.03 ↑
orrelation of the metabolite to the discriminatory model for the non-survivors.
P value (with Bonferroni correction) of the metabolite in the comparison
abolite in the comparison between H0 and H24 samples for the non-survivors;
iscovery rate for the P value calculated with the non-survivors; V1, variation in
concentration for the metabolites from H0 to H24 for the non-survivors; ↑,
concentration of the metabolite at H24 compared with H0. NS, non-significant
Fig. 4 Levels of key discriminatory metabolites and their relevant metabolic pathway in the comparison between SSS and SSN patients during
the H0-H24 evolution. a Levels of key discriminatory metabolites in the SSS and in SSN. The levels of the metabolites are calculated with the
average of time-trend change (ΔH24-H0). Averages of ΔH24-H0 for the survivors and non-survivors have been respectively shown and calibrated by
the standard deviation. *: p < 0.05. **: p < 0.01. a.u.: arbitrary unit; b relevant metabolic pathway for energy-related metabolites and amino acids
that vary differentially between SSS and SSN in the H0-H24 evolution. Metabolites marked by red color are those that increase in the SSN
compared to SSS in all the models. Solid flashes express a direct conversion between two metabolites and dotted lines represent undirect
conversions between two metabolites, according to KEGG metabolic pathway database
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SSS and SSN H0-H24 multilevel models
As shown in Table 4, different pairwise alterations of
relevant metabolites in the comparison between SSS andSSN groups indicate distinct trends in development
along with clinical therapy. Interestingly, most of these
metabolites related to septic shock evolution are in ac-
cordance with the discriminatory molecules found with
Table 5 Area under ROC for key metabolites that separate
septic shock survivors from non-survivors
AUROCH0
(n = 69)
AUROCH24
(n = 51)
AUROCH24-H0
(n = 51)
Lactate 0.74 0.75 0.73
Alanine 0.78 0.78 0.67
Glycoprotein (N-acetyl) 0.71 0.60 0.65
Glutamate 0.61 0.81 0.71
Glutamine 0.80 0.70 0.74
Pyruvate 0.81 0.83 0.79
Citrate 0.82 0.72 0.72
Creatinine 0.79 0.69 0.70
Phenylalanine 0.84 0.73 0.79
SOFA 0.60 0.64 0.61
SAPSII 0.62
n number of patients
Liu et al. Critical Care          (2019) 23:169 Page 10 of 12the H0 and H24 unpaired models. Besides the deregula-
tion of energy-related molecules, increases in four amino
acids may be associated with severe protein breakdown
and muscle wasting for the non-survivors. Notably,
serum concentrations in some amino acids, such as ala-
nine, glutamate, and phenylalanine, are otherwise docu-
mented to be involved with hemolysis associated with
sepsis [29]. Moreover, as shown in Fig. 4b, glutamate is
known to be a core amino acid for conversion into TCA
cycle intermediates [30]. Its elevation, as well as the ele-
vation of related amino acids such as glutamine and ala-
nine, is associated with increases in citrate.
Phenylalanine can be converted into fumarate. Increases
in phenylalanine in patients with poor outcomes have
been also reported in other studies [31–33]. The conver-
sion from amino acids to TCA cycle intermediates is
likely to provide supplementary energy during severe an-
oxic conditions, however, is detrimental for the out-
comes [34]. Creatinine is known to be an important
indicator for monitoring renal injury. Decreases in
N-acetyl glycoproteins may correspond to a breakdown
of proteins. Interestingly, it has been demonstrated by
DeCoux et al. [35] that inflammation-induced enriched
extracellular glycoproteins are associated with an opti-
mal response during septic shock.
The present study not only provides support for the
findings in our previous work, which investigated meta-
bolic differences between SSS and SSN at H0 [8], but
also reveals that different evolutions in the first 24 h
after admission to ICU between septic shock survivors
and non-survivors are linked to variations in metabolites
identified by this study. The ROC results shown in
Table 5 also show that the key metabolite discriminators
are good classifiers for separating SSN from SSS during
the first 24 h after ICU admission. We have reason tobelieve that sustained enrichment of energy-related me-
tabolites and amino acids can provide early warning of a
bad outcome.Conclusion
In the present study, we have investigated metabolic dif-
ferences between the survivors and non-survivors of sep-
tic shock with the samples obtained at ICU admission
and with those obtained 24 h later. We have provided
evidence that the sustained enrichment of energy-supply
metabolites and amino acids is predictive of a bad out-
come. We suggest that monitoring the relevant metabo-
lites in the first 24 h may help to evaluate early
therapeutic response.Additional files
Additional file 1 Table S1. Assignment of spectra recorded with one
exemplar serum sample from a septic shock patient. Figure S1.
Assignment of spectra recorded with an example of a representative
1H-NMR spectrum. The assigned peaks corresponding with the key
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the first 24 h (red dots) and those from the other non-survivors who died
from the second day to the seventh day after the first sampling (blue
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before statistical analyses. Blue dots: survivors, yellow dots: non-survivors.
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to corresponding discriminatory metabolites. The correlations between
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